Caribou Biosciences (CRBU)
NASDAQ:CRBU
Want to see CRBU full AI Analyst Report?
Top Page
Caribou Biosciences
(NASDAQ:CRBU)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▼(-31.82% Downside)
Action:Reiterated
Date:06/27/26
The score is held down primarily by weak financial performance (large losses and heavy cash burn) and bearish technicals (trading below major moving averages with negative MACD). Offsetting these, recent positive clinical and regulatory developments (RMAT status and strong trial readouts) provide meaningful upside optionality, while valuation is difficult to assess due to negative earnings and no dividend.
Positive Factors
Proprietary CRISPR platform & allogeneic focus
Caribou’s chRDNA-guided CRISPR platform and explicit focus on allogeneic, off-the-shelf cell therapies represent a durable business model advantage: potential for scalable manufacturing, lower per-patient cost vs autologous CAR-T, and recurring licensing/collaboration revenue streams that support long-term commercial optionality and partner interest.
Negative Factors
Persistent large operating losses
Sustained large operating losses reflect a cost base far exceeding current revenues. Over months this erodes capital, forces reliance on external financing, and can trigger dilutive raises or program cuts, constraining strategic flexibility and extending the timeline to self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary CRISPR platform & allogeneic focus
Caribou’s chRDNA-guided CRISPR platform and explicit focus on allogeneic, off-the-shelf cell therapies represent a durable business model advantage: potential for scalable manufacturing, lower per-patient cost vs autologous CAR-T, and recurring licensing/collaboration revenue streams that support long-term commercial optionality and partner interest.
Read all positive factors
Caribou Biosciences (CRBU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$166.62M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)2.38
Revenue Growth12.96%
EPS Growth12.51%
CountryUS
Employees147
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.42
Shares Outstanding99,180,570
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue15.85
Enterprise Value/Gross Profit19.18
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$8.75Price Target Upside297.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$23.61M
Caribou Biosciences Business Overview & Revenue Model
Company Description
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) an...
How the Company Makes Money
Caribou Biosciences primarily generates revenue through collaboration and licensing arrangements tied to its genome-editing technologies and development programs. These agreements typically include upfront payments, research funding or cost reimbu...
Caribou Biosciences Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.20M | 11.16M | 9.99M | 34.48M | 13.85M | 9.60M |
| Gross Profit | 9.26M | 7.51M | 6.07M | 30.95M | 10.21M | 8.61M |
| EBITDA | -111.97M | -145.03M | -145.19M | -98.35M | -95.71M | -65.61M |
| Net Income | -133.22M | -148.13M | -149.10M | -102.07M | -99.42M | -66.92M |
Balance Sheet | ||||||
| Total Assets | 149.00M | 175.37M | 313.31M | 432.21M | 373.76M | 442.36M |
| Cash, Cash Equivalents and Short-Term Investments | 117.63M | 139.34M | 209.54M | 328.83M | 247.66M | 375.83M |
| Total Debt | 26.95M | 27.23M | 26.49M | 27.11M | 27.75M | 259.00K |
| Total Liabilities | 46.98M | 53.19M | 60.36M | 63.81M | 72.89M | 54.53M |
| Stockholders Equity | 102.02M | 122.17M | 252.95M | 368.40M | 300.87M | 387.82M |
Cash Flow | ||||||
| Free Cash Flow | -101.64M | -112.35M | -144.71M | -104.90M | -97.42M | -35.64M |
| Operating Cash Flow | -101.25M | -110.99M | -138.20M | -93.29M | -90.97M | -32.52M |
| Investing Cash Flow | 76.84M | 102.24M | 86.61M | -68.18M | -93.25M | -176.40M |
| Financing Cash Flow | 7.05M | 4.82M | 16.72M | 154.30M | 2.13M | 433.43M |
Caribou Biosciences Technical Analysis
Negative
2.20
Price Trends
1.98
Negative
1.91
Negative
1.93
Negative
Market Momentum
-0.12
Positive
40.99
Neutral
31.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.98, and above the 200-day MA of 1.93, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 40.99 is Neutral, neither overbought nor oversold. The STOCH value of 31.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBU.
Caribou Biosciences Risk Analysis
Caribou Biosciences disclosed 84 risk factors in its most recent earnings report. Caribou Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Caribou Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $785.15M | ― | 87.31% | ― | ― | -1004.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $166.62M | -1.18 | -100.13% | ― | 12.96% | 12.51% | |
46 Neutral | $201.89M | -4.14 | -80.61% | ― | 43.21% | -15.55% | |
44 Neutral | $76.34M | -1.69 | -2748.16% | ― | ― | 43.68% | |
43 Neutral | $495.69M | -1.54 | -131.58% | ― | ― | 22.16% | |
38 Underperform | $18.64M | -0.11 | 6686.36% | ― | -45.80% | -0.16% |
* Healthcare Sector Average
CRBU
Caribou Biosciences
1.68
0.42
33.33%
SGMO
Sangamo Therapeutics
0.05
-0.50
-91.68%
CLLS
Cellectis SA
2.83
1.31
86.18%
CABA
Cabaletta Bio
3.04
1.52
100.00%
ELTX
Elicio Therapeutics
4.00
-3.72
-48.19%
VOR
Vor Biopharma
16.10
-16.30
-50.31%
Caribou Biosciences Corporate Events
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Caribou Biosciences Shareholders Decide Key Governance Matters
Neutral
Jun 18, 2026
On June 17, 2026, Caribou Biosciences, Inc. held its annual meeting of stockholders, where shareholders elected three Class II directors, Andrew Guggenhime, David Johnson, and Nancy Whiting, to terms extending to the 2029 annual meeting. Stockhold...
Business Operations and StrategyProduct-Related Announcements
Caribou Biosciences Highlights Strong Allogeneic CAR-T Trial Results
Positive
Jun 11, 2026
On June 11, 2026, Caribou Biosciences reported long-term phase 1 ANTLER trial data showing its off-the-shelf CD19-targeted CAR-T candidate vispa-cel achieved an 82% overall response rate, 67% complete response rate, and 17.1-month median progressi...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Caribou Biosciences Gains RMAT Status for CB-011 Therapy
Positive
Mar 31, 2026
On March 31, 2026, Caribou Biosciences announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myelo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.